LTRN A May 5th press release indicated that the FDA cleared Lantern Pharma, Inc.’s (NASDAQ:LTRN) LP-184 trial in triple ...

SHANGHAI, April 30, 2025 /PRNewswire/ -- Mabwell (688062), an innovation-driven biopharmaceutical company with entire industry chain, presented 6 study results of innovative drugs and platforms in ...

Therefore, USP1 has been considered as a synthetic lethal target with BRCA1/2-deficient and PARPi resistant tumors. Many investigational USP1 inhibitors have been discovered and developed, but key ...

The data looks competitive from an efficacy point of view, with no apparent safety signals, “supporting potential blockbuster status,” Bloomberg Intelligence’s John Murphy said in a note.

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. The phase 3 study linked the oral GLP-1 drug orforglipron to similar reductions in blood glucose and body ...

A team of researchers at Kyoto University says a clinical trial has shown the safety and efficacy of a treatment for Parkinson's disease using iPS-derived cells. The team at the university's ...

The group called Thursday’s findings a “positive readout” for orforglipron, adding that “Lilly achieves goal of reaching injectable like efficacy from oral orforglipron.” In the Phase III ACHIEVE-1 ...

In a press release, David A. Ricks, Lilly chair and CEO, said: "ACHIEVE-1 is the first of seven Phase III studies examining the safety and efficacy of orforglipron across people with diabetes and ...

Cumulative efficacy reached 62.9%, with protection observed against both RSV A and RSV B subtypes. Three vaccines are currently approved to prevent RSV-LRTD in people aged 60 years or older ...